• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《Charcot-Marie-Tooth 疾病儿科量表意大利版的验证》。

Validation of the Italian version of the Charcot-Marie-Tooth disease Pediatric Scale.

机构信息

Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.

Neuromuscular Omnicentre (NEMO)-Fondazione Serena Onlus, Genoa, Liguria, Italy.

出版信息

J Peripher Nerv Syst. 2020 Jun;25(2):138-142. doi: 10.1111/jns.12383. Epub 2020 May 26.

DOI:10.1111/jns.12383
PMID:32394473
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11725311/
Abstract

The Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS) is a Rasch-built clinical outcome measure of disease severity. It is valid, reliable, and responsive to change for children and adolescents aged 3 to 20 years. The aim of this study was to translate and validate an Italian version of the CMTPedS using a validated framework of transcultural adaptation. The CMTPedS (Italian) was translated and culturally adapted from source into Italian by two experts in CMT with good English language proficiency. The two translations were reviewed by a panel of experts in CMT. The agreed provisional version was back translated into English by a professional translator. The definitive Italian version was developed during a consensus teleconference by the same panel. CMT patients were assessed with the final version of the outcome measure and a subset had a second assessment after 2 weeks to evaluate test-retest reliability. Seventeen patients with CMT aged 5 to 20 years (eight female) were evaluated with the CMTPedS (Italian), and test-retest was performed in three patients. The CMTPedS (Italian) showed a high test-retest reliability. No patient had difficulty in completing the scale. The instructions for the different items were clearly understood by clinicians and therefore the administration of the outcome measure was straight forward and easily understood by the children assessed. The CMTPedS (Italian) will be used for clinical follow-up and in clinical research studies in the Italian population. The data is fully comparable to that obtained from the English language version.

摘要

Charcot-Marie-Tooth 疾病儿科量表(CMTPedS)是一种基于 Rasch 理论构建的疾病严重程度临床结局测量工具。它在 3 至 20 岁的儿童和青少年中具有有效性、可靠性和对变化的反应能力。本研究旨在使用经过验证的跨文化适应框架,将 CMTPedS 翻译成意大利语并进行验证。CMTPedS(意大利语)由两名具有良好英语语言能力的 CMT 专家从源语言翻译成意大利语,并进行文化适应性调整。这两个翻译版本由 CMT 专家小组进行了审查。经专家组同意的暂定版本由专业翻译人员翻译成英语。最终的意大利语版本是由同一专家组通过电话会议达成共识制定的。使用最终版本的结局测量工具对 17 名年龄在 5 至 20 岁的 CMT 患者(8 名女性)进行了评估,其中 3 名患者在 2 周后进行了第二次评估,以评估测试-重测信度。CMTPedS(意大利语)显示出较高的测试-重测信度。没有患者在完成量表方面有困难。临床医生清楚地理解了不同项目的说明,因此,该结局测量工具的管理对接受评估的儿童来说是直接和易于理解的。CMTPedS(意大利语)将用于意大利人群的临床随访和临床研究。数据与从英语版本获得的数据完全可比。

相似文献

1
Validation of the Italian version of the Charcot-Marie-Tooth disease Pediatric Scale.《Charcot-Marie-Tooth 疾病儿科量表意大利版的验证》。
J Peripher Nerv Syst. 2020 Jun;25(2):138-142. doi: 10.1111/jns.12383. Epub 2020 May 26.
2
Validation of the Italian version of the Charcot-Marie-Tooth Health Index.Charcot-Marie-Tooth 健康指数意大利版的验证。
J Peripher Nerv Syst. 2020 Sep;25(3):292-296. doi: 10.1111/jns.12397. Epub 2020 Jun 24.
3
[Validation of the Spanish version of the Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS)].[《夏科-马里-图思病儿童量表(CMTPedS)》西班牙语版本的验证]
Rev Neurol. 2022 Feb 1;74(3):78-82. doi: 10.33588/rn.7403.2021489.
4
Validation of the Italian version of the pediatric CMT quality of life outcome measure.验证小儿 CMT 生活质量结局测量的意大利语版本。
J Peripher Nerv Syst. 2022 Jun;27(2):127-130. doi: 10.1111/jns.12494. Epub 2022 May 3.
5
Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS.优化 CMTPedS 的标准化反应均值,细化临床试验纳入标准。
Ann Clin Transl Neurol. 2020 Sep;7(9):1713-1715. doi: 10.1002/acn3.51145. Epub 2020 Aug 6.
6
Development and validation of the Charcot-Marie-Tooth Disease Infant Scale.Charcot-Marie-Tooth 病婴儿量表的制定与验证。
Brain. 2018 Dec 1;141(12):3319-3330. doi: 10.1093/brain/awy280.
7
Translation and cross-cultural adaptation of the Charcot-Marie-Tooth disease Pediatric Scale to Brazilian Portuguese and determination of its measurement properties.Charcot-Marie-Tooth 病儿科量表的巴葡译及跨文化调适及其测量特性的测定。
Braz J Phys Ther. 2021 May-Jun;25(3):303-310. doi: 10.1016/j.bjpt.2020.07.008. Epub 2020 Aug 7.
8
Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.儿童型遗传性运动感觉神经病表型变异性。
JAMA Neurol. 2016 Jun 1;73(6):645-51. doi: 10.1001/jamaneurol.2016.0171.
9
Reliability of the Charcot-Marie-Tooth functional outcome measure.Charcot-Marie-Tooth 功能评定量表的信度。
J Peripher Nerv Syst. 2020 Sep;25(3):288-291. doi: 10.1111/jns.12406. Epub 2020 Aug 26.
10
Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease.过渡性结局指标:CMTPedS 与 CMTNSv2 在儿童、青少年和青年型腓骨肌萎缩症患者中的相关性。
J Peripher Nerv Syst. 2013 Jun;18(2):177-80. doi: 10.1111/jns5.12024.

引用本文的文献

1
Foot Assessment Clinical Scales in Charcot-Marie-Tooth Patients: A Scoping Review.夏科-马里-图思病患者足部评估临床量表:一项范围综述
Front Hum Neurosci. 2022 Jun 24;16:914340. doi: 10.3389/fnhum.2022.914340. eCollection 2022.
2
Validation of the Italian version of the pediatric CMT quality of life outcome measure.验证小儿 CMT 生活质量结局测量的意大利语版本。
J Peripher Nerv Syst. 2022 Jun;27(2):127-130. doi: 10.1111/jns.12494. Epub 2022 May 3.
3
[Validation of the Spanish version of the Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS)].

本文引用的文献

1
Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial.渐进性抗阻运动对儿童夏科-马里-图斯病的安全性和有效性:一项随机、双盲、假对照试验。
Lancet Child Adolesc Health. 2017 Oct;1(2):106-113. doi: 10.1016/S2352-4642(17)30013-5. Epub 2017 Jul 10.
2
Unique clinical and neurophysiologic profile of a cohort of children with CMTX3.CMTX3 患儿队列的独特临床和神经生理特征。
Neurology. 2018 May 8;90(19):e1706-e1710. doi: 10.1212/WNL.0000000000005479. Epub 2018 Apr 6.
3
Traduction française de l'échelle Charcot-Marie-Tooth Disease Pediatric Scale.
[《夏科-马里-图思病儿童量表(CMTPedS)》西班牙语版本的验证]
Rev Neurol. 2022 Feb 1;74(3):78-82. doi: 10.33588/rn.7403.2021489.
4
Translation and cross-cultural adaptation of the Charcot-Marie-Tooth disease Pediatric Scale to Brazilian Portuguese and determination of its measurement properties.Charcot-Marie-Tooth 病儿科量表的巴葡译及跨文化调适及其测量特性的测定。
Braz J Phys Ther. 2021 May-Jun;25(3):303-310. doi: 10.1016/j.bjpt.2020.07.008. Epub 2020 Aug 7.
Charcot-Marie-Tooth 病儿科量表的法译版。
Can J Neurol Sci. 2017 Nov;44(6):740-743. doi: 10.1017/cjn.2016.435. Epub 2017 Aug 17.
4
Natural history of Charcot-Marie-Tooth disease during childhood.儿童期夏科-马里-图斯病的自然病史。
Ann Neurol. 2017 Sep;82(3):353-359. doi: 10.1002/ana.25009.
5
Deterioration in gait and functional ambulation in children and adolescents with Charcot-Marie-Tooth disease over 12 months.12个月内患有夏科-马里-图思病的儿童和青少年的步态及功能性步行能力恶化情况。
Neuromuscul Disord. 2017 Jul;27(7):658-666. doi: 10.1016/j.nmd.2017.04.005. Epub 2017 Apr 19.
6
Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.儿童型遗传性运动感觉神经病表型变异性。
JAMA Neurol. 2016 Jun 1;73(6):645-51. doi: 10.1001/jamaneurol.2016.0171.
7
Report of the first Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-1) international workshop: Clearwater, Florida, November 30, 2011.1型强直性肌营养不良症首次结局测量(OMMYD-1)国际研讨会报告:佛罗里达州克利尔沃特,2011年11月30日。
Neuromuscul Disord. 2013 Dec;23(12):1056-68. doi: 10.1016/j.nmd.2013.07.004. Epub 2013 Sep 5.
8
Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.验证 Charcot-Marie-Tooth 疾病儿科量表作为残疾的结果测量指标。
Ann Neurol. 2012 May;71(5):642-52. doi: 10.1002/ana.23572.
9
Diagnosis, natural history, and management of Charcot-Marie-Tooth disease.夏科-马里-图思病的诊断、自然病史及治疗
Lancet Neurol. 2009 Jul;8(7):654-67. doi: 10.1016/S1474-4422(09)70110-3.
10
Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.患者报告结局(PRO)测量指标翻译与文化调适过程的良好实践原则:国际药物经济学与结果研究协会(ISPOR)翻译与文化调适特别工作组报告
Value Health. 2005 Mar-Apr;8(2):94-104. doi: 10.1111/j.1524-4733.2005.04054.x.